ALLO Share Price | Allogene Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Allogene Therapeutics, Inc.?

Market Cap: As of Jun 18, Allogene Therapeutics, Inc. has a market capitalization of 284.35 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Allogene Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -252.32 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 422.18 million and total assets of 548.71 million.

Q: What does Allogene Therapeutics, Inc. do?

Overview: Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company focused on developing and commercializing allogeneic T cell therapies for the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -60 Million (Quarterly Results - Mar 2025) Market cap: USD 284.35 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.71 Return on Equity: -61.39% Price to Book: 0.74Contact Details: Address: 210 E Grand Ave, SOUTH SAN FRANCISCO CA 94080-4811 Tel: 1 650 4572700 Website: http://www.allogene.com/

Q: Is Allogene Therapeutics, Inc. overvalued or undervalued?

As of 4 May 2022, the valuation grade for Allogene Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued given its negative performance metrics, including a price-to-book value of 0.81 and an EV to EBITDA of -0.16. Additionally, the return on capital employed (ROCE) stands at a staggering -224.08%, and the return on equity (ROE) is at -61.39%, reflecting substantial losses.In comparison to its peers, Allogene Therapeutics, Inc. shows a P/E ratio of -1.2018, while Enliven Therapeutics, Inc. has a P/E of -11.1774, and Wave Life Sciences Ltd. is at -9.0427, highlighting that Allogene is not alone in its struggles but still underperforms relative to its peers. The company's stock has significantly lagged behind the S&P 500, with a year-to-date return of -42.72% compared to the index's 2.44%. Overall, Allogene Therapeutics, Inc. appears to be overvalued in the current market environment.

Q: Is Allogene Therapeutics, Inc. technically bullish or bearish?

As of 18 August 2025, the technical trend for Allogene Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals: the MACD is mildly bullish on both weekly and monthly time frames, while the moving averages indicate a mildly bearish trend on the daily. The Bollinger Bands suggest a bullish outlook weekly but a mildly bearish one monthly. Additionally, the KST is mildly bullish weekly but bearish monthly, and the Dow Theory indicates a mildly bearish trend weekly with no trend monthly.In terms of performance, the stock has returned 3.42% over the past week and 11.01% over the past month, outperforming the S&P 500, which returned 1.05% and 2.33% respectively. However, the year-to-date return is -43.19%, significantly underperforming the S&P 500's 12.22%. Over the longer term, the stock has seen substantial declines, with a 5-year return of -96.82% compared to the S&P 500's 96.61%.

Results Declared: Allogene Therapeutics, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.4 M

Shareholding (Dec 2025)

FII

13.23%

Held by 90 FIIs

DII

21.04%

Held by 61 DIIs

Promoter

25.79%

How big is Allogene Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Allogene Therapeutics, Inc. has a market capitalization of 284.35 million, with net sales of 0.00 million and a net profit of -252.32 million over the latest four quarters. The company reported shareholder's funds of 422.18 million and total assets of 548.71 million as of Dec'24.

View full answer

What does Allogene Therapeutics, Inc. do?

22-Jun-2025

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company developing allogeneic T cell therapies for cancer treatment. It has a market cap of $284.35 million and reported a net profit loss of $60 million as of March 2025.

View full answer

Who are in the management team of Allogene Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Allogene Therapeutics, Inc. includes Dr. Arie Belldegrun (Executive Chairman), Dr. David Chang (President and CEO), and Mr. Joshua Kazam (Co-Founder). The Board of Directors also features independent members such as Mr. David Bonderman and Dr. Franz Humer.

View full answer

Is Allogene Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 4, 2022, Allogene Therapeutics, Inc. is considered overvalued due to significant financial losses, reflected in metrics like a price-to-book value of 0.81, a negative P/E ratio of -1.2018, and a year-to-date return of -42.72%, indicating a deterioration in its financial standing compared to peers and the S&P 500.

View full answer

Is Allogene Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 18, 2025, Allogene Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, having returned 3.42% over the past week and 11.01% over the past month, but is down 43.19% year-to-date compared to the S&P 500's 12.22% gain.

View full answer

Compare Allogene Therapeutics, Inc. with Similar Stocks

Anavex Life Sciences Corp.Alpine Immune Sciences, Inc.Enliven Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 595 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.77

Return on Equity

-66.48%

Price to Book

1.89

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-39 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

57.86%

6 Months

79.67%

1 Year

31.55%

2 Years

-48.12%

3 Years

-55.98%

4 Years

-77.74%

5 Years

-93.34%

Allogene Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

2.15%

EBIT to Interest (avg)

-269.24

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.71

Sales to Capital Employed (avg)

0.00

Tax Ratio

0.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

94.47%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.89

EV to EBIT

-1.56

EV to EBITDA

-1.65

EV to Capital Employed

4.93

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-316.29%

ROE (Latest)

-66.48%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 47 Schemes (39.95%)

Foreign Institutions

Held by 90 Foreign Institutions (13.23%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 6.28% vs 18.66% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-39.30",
          "val2": "-41.80",
          "chgp": "5.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-38.80",
          "val2": "-41.40",
          "chgp": "6.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 25.89% vs 21.30% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-194.60",
          "val2": "-243.80",
          "chgp": "20.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "0.20",
          "chgp": "450.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "-15.70",
          "chgp": "84.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-190.90",
          "val2": "-257.60",
          "chgp": "25.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-11,703,727.30%",
          "chgp": "11,70,372.73%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-39.30

-41.80

5.98%

Interest

0.30

Exceptional Items

0.00

Consolidate Net Profit

-38.80

-41.40

6.28%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 6.28% vs 18.66% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-194.60

-243.80

20.18%

Interest

1.10

0.20

450.00%

Exceptional Items

-2.40

-15.70

84.71%

Consolidate Net Profit

-190.90

-257.60

25.89%

Operating Profit Margin (Excl OI)

0.00%

-11,703,727.30%

11,70,372.73%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 25.89% vs 21.30% in Dec 2024

All Annual Results

Company CV

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.

Company Coordinates

Company Details

210 E Grand Ave , SOUTH SAN FRANCISCO CA : 94080-4811

Tel: 1 650 4572700

http://www.allogene.com/

Registrar Details